DB-OTO clinical trials

A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations

This study is testing a new gene therapy, DB-OTO, for children under 18 with hearing loss caused by a specific gene change (otoferlin mutation). Researchers want to see if it's safe, well-tolerated, and effective in improving their hearing.